A11 peptide

A11 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-EYVQTVKSSKG-OH

H-Glu-Tyr-Val-Gln-Thr-Val-Lys-Ser-Ser-Lys-Gly-OH

11

95.68%

C₅₃H₈₈N₁₄O₁₉

1225.34

Synthetic

Powder

A11 (ANXA1-derived 11 amino acid–long peptide) is a peptide derived from amino acid residues 20-30 of the ANXA1 N-terminus fused to the cell penetrating peptide CPP. A11 blocks ANXA1 competition with the E3 ubiquitin ligase Cbl for binding EphA2, enhancing Cbl-mediated EphA2 ubiquitination and degradation, and reducing the oncogenic mechanism of the ANXA1– EphA2 interaction in nasopharyngeal carcinoma (NPC). A11 can suppress NPC cell growth in vitro and in vivo.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Feng et al (2020) ANXA1 Binds and Stabilizes EphA2 to Promote Nasopharyngeal Carcinoma Growth and Metastasis. Cancer Res. 80(20) 4386 PMID: 32737118

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.